Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

Essential breast cancer medicines

ASH 2025: Latest video and news updates here

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response